Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
JCO Oncology Practice|June 30, 2025
Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung CancerRotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, et al.
Cancer Research Communications|March 16, 2023
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal CancerRyon P Graf, Virginia Fisher, James Creeden, et al.
JAMA Network Open|May 2, 2023
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With ImmunotherapyCharu Aggarwal, Rotem Ben-Shachar, Yinjie Gao, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?Sheetal M Kircher, Caitlin R Meeker, Halla Nimeiri, et al.
JAMA Network Open|January 22, 2024
Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer CohortWade T Iams, Matthew Mackay, Rotem Ben-Shachar, et al.
The Oncologist|May 1, 2015
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204Jerome C Landry, Yang Feng, Roshan S Prabhu, et al.
International Journal of Radiation Oncology, Biology, Physics|March 26, 2014
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolizationRyan Hickey, Mary F Mulcahy, Robert J Lewandowski, et al.
Cancer|January 5, 2013
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204Jerome C Landry, Yang Feng, Steven J Cohen, et al.
JCO Precision Oncology|January 20, 2022
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal AdenocarcinomaLiangliang Zhang, Omar Hamdani, Ole Gjoerup, et al.
Cancer Research Communications|October 15, 2025
Molecular Characterization of Oncogenic Gene Fusions in a Large Real-World Cohort of Solid TumorsLisa Gai, Bradley Bowles, Adam J Hockenberry, et al.
Pageof 4